Evidence map›Paper›PMID 35225872›Full record

ArticleAntibodies (Basel, Switzerland)2022

More Than Meets the Kappa for Antibody Superantigen Protein L (PpL).

Wei-Li Ling, Joshua Yi Yeo, Yuen-Ling Ng, Anil Wipat, Samuel Ken-En Gan

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Wei-Li LingAntibody & Product Development Laboratory, Experimental Drug Development Centre-Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.
Joshua Yi YeoAntibody & Product Development Laboratory, Experimental Drug Development Centre-Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.ORCID 0000-0002-0253-0238
Yuen-Ling NgNewcastle Research and Innovation Institute (NewRIIS), Singapore 609607, Singapore.
Anil WipatSchool of Computing, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Samuel Ken-En GanAntibody & Product Development Laboratory, Experimental Drug Development Centre-Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.ORCID 0000-0001-9936-5090
Agency for Science, Technology and Research · SGAlbany Molecular Research (Singapore) · SGNewcastle University · GB

Funding

A*STAR Joint Council Office JCO1334i00050
6 · The paper itself

Abstract

Immunoglobulin superantigens play an important role in affinity purification of antibodies and the microbiota-immune axis at mucosal areas. Based on current understanding,

Indexed as

IgG1immunoglobulinPertuzumabsuperantigenTrastuzumabVH familiesVK families

Identifiers

PMID35225872
PMCPMC8883962
OpenAlexW4220760940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.